Intra-Cellular Therapies Current Ratio 2013-2021 | ITCI

Intra-Cellular Therapies current ratio from 2013 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Intra-Cellular Therapies Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.60B $0.05B 11.93
2021-03-31 $0.65B $0.04B 16.35
2020-12-31 $0.69B $0.04B 18.75
2020-09-30 $0.75B $0.04B 19.59
2020-06-30 $0.42B $0.04B 10.40
2020-03-31 $0.46B $0.03B 14.83
2019-12-31 $0.23B $0.04B 6.36
2019-09-30 $0.26B $0.03B 7.77
2019-06-30 $0.29B $0.03B 8.87
2019-03-31 $0.32B $0.03B 9.59
2018-12-31 $0.36B $0.04B 9.79
2018-09-30 $0.38B $0.03B 13.16
2018-06-30 $0.41B $0.02B 21.64
2018-03-31 $0.44B $0.02B 22.55
2017-12-31 $0.47B $0.01B 33.02
2017-09-30 $0.33B $0.01B 28.08
2017-06-30 $0.35B $0.01B 50.10
2017-03-31 $0.37B $0.02B 22.77
2016-12-31 $0.39B $0.01B 36.86
2016-09-30 $0.54B $0.14B 3.85
2016-06-30 $0.45B $0.02B 23.05
2016-03-31 $0.46B $0.01B 51.74
2015-12-31 $0.48B $0.01B 77.15
2015-09-30 $0.51B $0.01B 49.32
2015-06-30 $0.21B $0.01B 22.82
2015-03-31 $0.24B $0.02B 16.21
2014-12-31 $0.13B $0.01B 12.41
2014-09-30 $0.14B $0.00B 38.43
2014-06-30 $0.14B $0.00B 51.55
2014-03-31 $0.15B $0.00B 37.42
2013-12-31 $0.04B $0.01B 5.60
2013-09-30 $0.05B $0.01B 6.06
2013-06-30 $0.00B $0.00B 0.00
2013-03-31 $0.00B $0.00B 0.16
2012-12-31 $0.00B 0.00
2012-09-30 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.590B $0.023B
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86